Croles FN, et al. - The researchers intended to provide evidence in support of the updated guidelines for the management of pregnant women with hereditary thrombophilia for lowering the risk of a first venous thromboembolism (VTE) in pregnancy. Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden ought to be taken into account for antepartum or postpartum thrombosis prophylaxis, or both. The authors recommended against the prescription of thrombosis prophylaxis on the basis of thrombophilia and family history alone, for women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation. These served as a framework for future guidelines on pregnancy-associated VTE risk.